RegulatoryOfficial

FDA issues draft guidance on electronic submission of IDE applications to CDRH and CBER

🇺🇸 FDA CBER · Tue 27 Oct 2026

The draft introduces existing resources for electronic IDE submissions; binding standards, a timetable and exemption criteria are due only when the guidance is finalised.

The US Food and Drug Administration has issued a draft guidance for sponsors of Investigational Device Exemption (IDE) applications to the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER). The guidance is dated 27 October 2026.

In its current form, the document introduces sponsors to publicly available resources and related content developed to support electronic submission of IDE applications that are not otherwise exempted. It is described as one of several steps in FDA's commitment to develop electronic submission templates, which are meant to act as guided preparation tools. The agency says the aim is greater consistency in submissions and more efficient review.

The draft does not yet set out the full requirements. According to FDA, the finalised guidance will provide further standards for submission in electronic format, a timetable for establishing those standards, and criteria for waivers of and exemptions from the requirements.

Comments on the draft can be submitted online or in writing until 28 December 2026 under docket number FDA-2026-D-11188. Written comments go to Dockets Management, Food and Drug Administration, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852. FDA notes that comments may be made at any time, but those received before the close date are the ones it will consider before starting work on the final version.

What it means for your team

  • Sponsors of IDEs reviewed by CDRH or CBER should read the draft and the resources it points to, and begin planning for electronic submission preparation.
  • Implementation dates, detailed standards and exemption or waiver criteria are not yet fixed; they are expected in the final guidance, so no compliance deadline can be assumed from the draft.
  • Teams wishing to influence the final text should file comments under docket FDA-2026-D-11188 by 28 December 2026.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Regulatory All →